Search Results - "Gil, Eva Maria Ciruelos"

Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer by Ciruelos Gil, Eva Maria

“…Abstract Approximately 70−75% of breast cancers express the estrogen receptor (ER), indicating a level of dependence on estrogen for growth. Endocrine therapy…”
Get full text

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer by BASELGA, José, GOMEZ, Patricia, GOEMINNE, Jean-Charles, GRAAS, Marie-Pascale, KENNEDY, M. John, CIRUELOS GIL, Eva Maria, SCHNEEWEISS, Andreas, ZUBEL, Angela, GROOS, Jutta, MELEZINKOVA, Helena, AWADA, Ahmad, GREIL, Richard, BRAGA, Sofia, CLIMENT, Miguel A, WARDLEY, Andrew M, KAUFMAN, Bella, STEMMER, Salomon M, PEGO, António, CHAN, Arlene

“…Epidermal growth factor receptor is overexpressed in metastatic triple-negative breast cancers (mTNBCs), an aggressive subtype of breast cancer. Our randomized…”
Get full text

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer by Guerrero-Zotano, Ángel, Belli, Stefania, Zielinski, Christoph, Gil-Gil, Miguel, Fernandez-Serra, Antonio, Ruiz-Borrego, Manuel, Ciruelos Gil, Eva Maria, Pascual, Javier, Muñoz-Mateu, Montserrat, Bermejo, Begoña, Margeli Vila, Mireia, Antón, Antonio, Murillo, Laura, Nissenbaum, Bella, Liu, Yuan, Herranz, Jesús, Fernández-García, Daniel, Caballero, Rosalía, López-Guerrero, José Antonio, Bianco, Roberto, Formisano, Luigi, Turner, Nicholas, Martín, Miguel

“…In hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly to cyclin-dependent kinase…”
Get full text

Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer by Baird, Richard, Oliveira, Mafalda, Gil, Eva Maria Ciruelos, Patel, Manish R, Bermejo de las Heras, Begoña, Ruiz-Borrego, Manuel, García-Corbacho, Javier, Armstrong, Anne, Banerji, Udai, Twelves, Chris, Boni, Valentina, Incorvati, Jason, Kabos, Peter, Cohen, Adam L, de Paula, Bruno, Rodríguez, Marta Capelán, Wang, Judy S, Hernando, Christina, Gonzalez, Alejandro Falcón, Ruiz, Ivan Victoria, Lai-Kwon, Julia, Afghani, Anosheh, Vaklavas, Christos, Brier, Tim, Fox, Steven, Kirova, Bistra, Klinowska, Teresa, Leach, Chris, Lindemann, Justin PO, Mather, Richard, Maudsley, Rhiannon, Morrow, Christopher J, Sathiyayogan, Nitharsan, Sykes, Andy, Zhang, Li, Hamilton, Erika

“…Background: AZD9833 is an oral selective estrogen receptor (ER) antagonist and degrader (SERD) in Phase 2 clinical development for the treatment of ER+ HER2−…”
Get full text

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial by Salvador Bofill, Javier, Moreno Anton, Fernando, Rodriguez Sanchez, Cesar Augusto, Galve Calvo, Elena, Hernando Melia, Cristina, Ciruelos Gil, Eva Maria, Vidal, Maria, Jiménez-Rodriguez, Begoña, De la Cruz Merino, Luis, Martínez Jañez, Noelia, Villanueva Vazquez, Rafael, de Toro Salas, Ruben, Anton Torres, Antonio, Alvarez Lopez, Isabel Manuela, Gavila Gregori, Joaquin, Quiroga Garcia, Vanesa, Vicente Rubio, Elena, De la Haba-Rodriguez, Juan, Gonzalez-Santiago, Santiago, Diaz Fernandez, Nieves, Barnadas Molins, Agusti, Cantos Sanchez de Ibargüen, Blanca, Delgado Mingorance, Juan Ignacio, Bellet Ezquerra, Meritxell, de Casa, Sonia, Gimeno, Asuncion, Martin, Miguel

“…Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish women. Ribociclib in combination with endocrine…”
Get full text

Development and validation of a gene expression-based Breast Cancer Purity Score by Barreca, Marco, Dugo, Matteo, Galbardi, Barbara, Győrffy, Balázs, Valagussa, Pinuccia, Besozzi, Daniela, Viale, Giuseppe, Bianchini, Giampaolo, Gianni, Luca, Callari, Maurizio

“…The prevalence of malignant cells in clinical specimens, or tumour purity, is affected by both intrinsic biological factors and extrinsic sampling bias…”
Get full text

Efficacy and safety of first-line (1L) pertuzumab (P), trastuzumab (T), and docetaxel (D) in HER2-positive MBC (CLEOPATRA) in patients previously exposed to trastuzumab by Ciruelos Gil, Eva Maria, Brufsky, Adam, Im, Young-Hyuck, Kim, Sung-Bae, Clark, Emma, Knott, Adam, Ross, Graham, Miles, David

“…Abstract only 600 Background: CLEOPATRA is a global phase III trial of P + T + D vs placebo + T + D in HER2-positive 1L MBC. Results showed a significant…”
Get full text

Estrogen receptor in HER2-positive early breast cancer: Two different diseases? by Ciruelos Gil, Eva Maria, Ghanem, Ismael, Manso, Luis, Hoyos, Sergio, Castañeda, Carlos, Lora, David, Mendiola, Cesar, Sancho, Blanca, Pascual, Tomas, Cortes-Funes, Hernan

“…Abstract only 642 Background: HER2+ breast cancer (BC) is a well characterized subtype of BC, due to the predictive value of HER2 overexpression for anti-HER2…”
Get full text

Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metastatic breast cancer who experienced complete or partial remission or disease stabilization during at least 3 years: LongHer study by Zamora, Pilar, Fresno-Vara, Juan Angel, Gámez-Pozo, Angelo, Perez-Carrion, Ramon, Manso, Luis, Crespo Massieu, Carmen, Mendiola, Cesar, Alvarez, Isabel, Margeli Vila, Mireia, Bayo Calero, Juan Lucas, Gonzalez, Xavier, Santaballa, Ana, Ciruelos Gil, Eva Maria, Afonso Gomez, Ruth, Lao Romera, Juan, Catalan, Gustavo, Alvarez Gallego, Jose Valero, Miramon Lopez, Jose, Salvador Bofill, Francisco Javier, Ruiz Borrego, Manuel

“…Abstract only e11081 Background: Trastuzumab has shown an improvement in survival outcomes among patients with HER2+ metastatic breast cancer (MBC)…”
Get full text

Update on adjuvant hormonal treatment of early breast cancer by Lao Romera, Juan, Puertolas Hernández, Teresa de Jesús, Peláez Fernández, Ignacio, Sampedro Gimeno, Teresa, Fernández Martínez, Roberto, Fernández Pérez, Isaura, Iranzo González Cruz, Vega, Illarramendi Mañas, José Juan, Garcerá Juan, Salvador, Ciruelos Gil, Eva María

Get full text

Update on adjuvant hormonal treatment of early breast cancer by Lao Romera, Juan, Puertolas Hernández, Teresa de Jesús, Peláez Fernández, Ignacio, Sampedro Gimeno, Teresa, Fernández Martínez, Roberto, Fernández Pérez, Isaura, Iranzo González Cruz, Vega, Illarramendi Mañas, José Juan, Garcerá Juan, Salvador, Ciruelos Gil, Eva María

“…Clinical trials conducted over the last two decades have demonstrated that 5 years of treatment with tamoxifen (TAM) after local treatment in postmenopausal…”
Get full text